Blood tests offer a less invasive and more accessible means of detecting Alzheimer disease; Democrats address a year-long Adderall shortage; A new study shows significantly improved clinical outcomes in Type 2 diabetes management with a digital behavioral therapy app.
Blood Tests for Widespread Alzheimer Diagnosis Likely by 2023
A blood test for diagnosing Alzheimer disease may become available to the public in the very near future, as experts predict its availability in 2023, according to Reuters. This groundbreaking development offers a less invasive and more accessible means of detecting Alzheimer disease, potentially leading to earlier diagnoses and better treatment options. This news brings hope to individuals and families impacted by this common form of dementia, as it could transform the landscape of Alzheimer disease diagnosis and care.
Year-Long Adderall Shortage Continues
Democrats are seeking answers regarding a year-long shortage of Adderall, a medication used to treat attention-deficit/hyperactivity disorder, according to The Hill. In a letter to the FDA and the Drug Enforcement Administration, lawmakers expressed concerns about the shortage’s impact on patients who depend on the medication. The shortage has created difficulties for patients in accessing the necessary treatment, raising questions about supply chain issues and potential actions to address the problem.
Digital Therapeutic AspyreRx Enhances T2D Management
A recent subgroup analysis of AspyreRx (formerly BT-001) in a pivotal trial for type 2 diabetes (T2D) demonstrated that when used in conjunction with standard of care and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the digital behavioral therapy app led to substantial clinical improvements compared with those not using AspyreRx, according to Better Therapeutics. The study, which involved 160 participants, resulted in an average reduction of 0.7% in hemoglobin A1C levels at 90 days, surpassing the 0.4% reduction seen among in the control arm of the BT-001 pivotal clinical trial population. Those combining GLP-1 RAs with AspyreRx also exhibited greater hemoglobin A1C reduction, weight loss, and reduced medication use at day 180.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Mental Health Diagnoses, Care Challenges Rise Among US Youth, Report Finds
April 26th 2024While behavioral health care utilization has been rising, the treatment landscape has been worsening. New findings show that 20% of youths did not receive any form of treatment within 3 months of their initial behavioral health diagnosis.
Read More
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More